⌘K
t
Vulpes Testudo Fund, a fund closely associated with Scancell Holdings plc Non-Executive Director Martin Diggle, purchased 497,764 ordinary shares in the company between 15 May 2025 and 20 May 2025 at 9 pence per share. Following this transaction, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 130,884,801 ordinary shares, representing 12.62% of Scancell Holdings plc.
| Date | 21 May 2025 |
| Time | 07:00:10 |
| Category | Director/PDMR dealings |
| ID | 4907J |
21 May 2025
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non- Executive Director, has purchased 497,764 ordinary shares of 0.9p each ('Ordinary Shares') in the Company between 15 May 2025 and 20 May 2025 at a price of 9 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 130,884,801 ordinary shares representing 12.62% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||||||
|
a) |
Name |
Vulpes Testudo Fund |
|||||||||
|
2 |
Reason for the notification |
||||||||||
|
a) |
Position/status |
Fund closely associated with Martin Diggle, Non-Executive Director |
|||||||||
|
b) |
Initial notification/Amendment |
Initial notification |
|||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a) |
Name |
Scancell Holdings plc |
|||||||||
|
b) |
LEI |
2138008RXEG856SNP666 |
|||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.9 pence each |
|||||||||
|
b) |
Identification Code |
GB00B63D3314 |
|||||||||
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
|||||||||
|
|
|
|
|||||||||
|
d) |
Price(s) and volume(s) |
|
|||||||||
|
e) |
Aggregated information - Aggregated volume - Price |
497,764 Ordinary Shares 9 pence per Ordinary Share |
|||||||||
|
f) |
Date of the transaction |
|
|||||||||
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|||||||||
|
For further information, please contact: |
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Phil L'Huillier, CEO |
|
|
Sath Nirmalananthan, CFO |
|
|
Dr Jean-Michel Cosséry, Non-Executive Chairman |
|
|
|
|
|
Panmure Liberum (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
|
|
|
|
|
WG Partners LLP (Joint Broker) David Wilson, Claes Spang |
+44 (0) 20 3705 9330
|
|
|
|
|
ICR Healthcare Mary-Jane Elliott, Stephanie Cuthbert, Chris Welsh |
+44 (0) 20 3709 5700 |
About Scancell
Scancell (LSE:SCLP) develops immunotherapies for a Cancer-free future by enhancing long-lasting tumour specific immunity. As a clinical stage biotechnology company with deep roots in cancer immunology and translational research, Scancell develops tumour targeted off-the-shelf vaccines, with highly favourable safety and durable systemic immune responses. Scancell's lead product, iSCIB1+, a DNA vaccine, is currently showing strong promise on top of checkpoint therapies in a multi-arm phase 2 study in first-line melanoma. The second vaccine, Modi-1, is being investigated in a phase 2 study in a broad range of solid tumours. Scancell is also developing a pipeline of high affinity antibodies targeting tumour specific glycans using its proprietary platforms. Two of these antibodies are now being developed in major biopharma partnerships, and a further two antibodies targeting lung and epithelial cancers are actively being developed in-house.